Neuroprotective Effects of Transplanted iPSC-Derived Neural Precursors in Huntington’s Disease Models.

Establishment of six human induced pluripotent stem cell lines from healthy Central Asian donors (IPBi115-A, IPBi116-A, IPBi117-A, IPBi119-A, IPBi124-A, and IPBi129-A)

Toward standardized iPSC testing: Insights from a multi-year international Quality Assessment Round

Generation of human induced pluripotent stem cell lines from healthy Korean donors (IPBi101-A, IPBi102-A, IPBi103-A, IPBi105-A, IPBi107-A, IPBi108-A, IPBi110-A, IPBi111-A, IPBi113-A, and IPBi114-A).

ISSCR standards for the use of human stem cells in basic research.

A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of Huntington’s disease.

Lessons learnt, and still to learn, in first in human stem cell trials.

Mitochondrial genome mutations and neuronal dysfunction of induced pluripotent stem cells derived from patients with Alzheimer's disease.

SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington’s disease.

Therapeutic Effect of BDNF-Overexpressing Human Neural Stem Cells (F3.BDNF) in a Contusion Model of Spinal Cord Injury in Rats

Screening method for candidate drugs for Huntington's disease using induced pluripotent stem cells derived from Huntington's disease patients. (101535253)

Pharmaceutical composition for the treatment of stroke comprising neural precursor cells derived from human induced pluripotent stem cells. (101516352)